Sycosis Barbae Treated With Bimekizumab

    Matiar Madanchi, Riccardo Curatolo, Lorenzo Pelloni, Hazem A. Juratli
    Studysummary In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results